Last reviewed · How we verify
MK5172 /MK8742
MK5172/MK8742 is a combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.
MK5172/MK8742 is a combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 6).
At a glance
| Generic name | MK5172 /MK8742 |
|---|---|
| Sponsor | Istituto Clinico Humanitas |
| Drug class | Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) |
| Target | HCV NS3/4A protease and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease (Hepatitis C) |
| Phase | Phase 3 |
Mechanism of action
MK5172 (grazoprevir) inhibits the NS3/4A serine protease essential for HCV polyprotein processing, while MK8742 (elbasvir) inhibits the NS5A protein required for viral RNA replication and virion assembly. Together, these direct-acting antivirals target multiple steps of the HCV lifecycle to achieve sustained virologic response.
Approved indications
- Chronic hepatitis C virus infection (genotype 1, 4, 6)
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)
- VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C (NA)
- Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) (PHASE2)
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) (PHASE3)
- An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) (PHASE3)
- A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK5172 /MK8742 CI brief — competitive landscape report
- MK5172 /MK8742 updates RSS · CI watch RSS
- Istituto Clinico Humanitas portfolio CI